# Dronedarone

Drug · id `cardio:dronedarone` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Multaq

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Dronedarone, sold as Multaq, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug. The label read lists one use: lowering the chance of being admitted to hospital for atrial fibrillation, for patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The label says the mechanism of action is unknown and that the medicine has antiarrhythmic properties belonging to all four Vaughan-Williams classes. It carries a boxed warning: in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.

## Technical summary

RxNorm ingredient 233698 (dronedarone); UNII JQZ1L091Y2 (exact: the openFDA record of the label lists it and RxNorm gives it for the ingredient); the label describes the hydrochloride salt (RxNorm 736680). MeSH descriptor D000077764 is Dronedarone; its record lists the pharmacological action Anti-Arrhythmia Agents and says dronedarone was indexed under amiodarone analogs and derivatives from 1999 to 2018. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic \[EPC\]). The label read is the Sanofi-Aventis U.S. LLC label for Multaq tablets, application NDA022425, effective 2025-05-29 in openFDA. This page records label indications, the class, the mechanism sentences and the boxed warning only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with decompensated heart failure or permanent atrial fibrillation, as described in a US Multaq label boxed warning

Recipient: Recipient not specified; Population: Patients with symptomatic heart failure and recent decompensation requiring hospitalization, patients with NYHA class IV heart failure, and patients with permanent atrial fibrillation, as the boxed warning describes the risks. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning on an increased risk of death, stroke and heart failure in patients with decompensated heart failure or permanent atrial fibrillation. It says that in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and that for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with symptomatic heart failure and recent decompensation requiring hospitalization, patients with NYHA class IV heart failure, and patients with permanent atrial fibrillation, as the boxed warning describes the risks. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the label's boxed warning statements of risk only. The warning also states two contraindications; those are the label's and are not repeated as advice. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph, heart failure. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Label passage quoted in the research quote table (LB-09).
  2. Supports: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first paragraph, permanent atrial fibrillation. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Label passage quoted in the research quote table (LB-10).
  3. Background: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Effective date of the label text read, 20250529.

## Context: Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Multaq (dronedarone tablets, Sanofi-Aventis U.S. LLC, application NDA022425; the version dated 2025-05-29 in openFDA) describes dronedarone as an antiarrhythmic drug. It lists reducing the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. A second openFDA Multaq record from a repackager was not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], highlights sentence. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indication statement. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06).
  3. Background: openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective\_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.) <https://api.fda.gov/drug/label.json?search=set_id:%227fa41601-7fb5-4155-8e50-2ae903f0d2d6%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:14Z. Source state: Current. Version fingerprint: 54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662.
     How it applies: Effective date of the label text read, 20250529.

## Connected pages

- Dronedarone is an antiarrhythmic (FDA established pharmacologic class in RxClass): Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- FDA label lists reducing the risk of hospitalization for atrial fibrillation, in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-dronedarone-label-indications` and its context]
- MeSH says dronedarone was indexed under amiodarone analogs and derivatives from 1999 to 2018: Amiodarone (`cardio:amiodarone`)
- The label's boxed warning names symptomatic heart failure with recent decompensation, and NYHA class IV heart failure, as groups in which the medicine doubles the risk of death: Heart failure (`cardio:heart-failure`)
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: cd5dbb65968ef550f8a45a68f369cb85b500d1cc25ad9e00884c1372438c1798
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
